![]() Incanthera Incanthera is a company that engages in the development of novel treatments for solid tumors (cancers). | ![]() G1 Therapeutics G1 Therapeutics is a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. | ![]() Alpine Immune Sciences Alpine Immune Sciences is a biotechnology company that develops protein-based immunotherapies. | Oncolytics Biotech Oncolytics Biotech is a company developing Pelareorep, an intravenously delivered immuno-oncolytic virus, used for the treatment of solid tumors and hematological malignancies. | |
Founding Date | Founding Date 2010 | Founding Date 2008 | Founding Date 2015 | Founding Date 1998 |
Type | Type Private | Type Public | Type Subsidiary | Type Public |
Tags | ||||
Locations | Locations Manchester, GB HQ Bradford, GB | Locations Durham, US HQ | Locations Seattle, US HQ | Locations Calgary, CA HQ Calgary, CA San Diego, US |
Employees | Employees N/A | Employees 17015% increase | Employees 484% decrease | Employees 28 |
Valuation ($) | Valuation ($) N/A | Valuation ($) 377.2 m | Valuation ($) N/A | Valuation ($) 93.9 m |
Financial | ||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $82.5m (FY, 2023) | Revenue (est.) $58.9m (FY, 2023) | Revenue (est.) N/A |
Cost of goods | Cost of goods N/A | Cost of goods $7.2m (FY, 2023) | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit $75.3m (FY, 2023) | Gross profit N/A | Gross profit N/A |
Net income | Net income N/A | Net income ($48m) (FY, 2023) | Net income ($32.2m) (FY, 2023) | Net income ($28.8m) (FY, 2025) |
Funding | ||||
Total funding raised | Total funding raised $ 1.1m | Total funding raised $ 289.6m | Total funding raised $ 49.3m | Total funding raised $ 24m |

G1 Therapeutics is a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer.
View company
Alpine Immune Sciences is a biotechnology company that develops protein-based immunotherapies.
View companyOncolytics Biotech is a company developing Pelareorep, an intravenously delivered immuno-oncolytic virus, used for the treatment of solid tumors and hematological malignancies.
View company